<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409668</url>
  </required_header>
  <id_info>
    <org_study_id>B2007:070</org_study_id>
    <nct_id>NCT01409668</nct_id>
  </id_info>
  <brief_title>Efficacy of Two Yogurt Formulations in Healthy Humans</brief_title>
  <acronym>MPH</acronym>
  <official_title>Efficacy of Two Yogurt Formulations as Health Promoting Agents in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Micropharma Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of consumption of: L.Ruteri containing
      yogurt, L.Fermentum containing yogurt VERSUS placebo on plasma lipids, as well as
      gastrointestinal microflora distribution in hyperlipidemic individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol Metabolism</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>L. Amylovorus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L. Fermentum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L. Amylovorus</intervention_name>
    <description>L. Amylovorus</description>
    <arm_group_label>L. Amylovorus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L. Fermentum</intervention_name>
    <description>L. Fermentum</description>
    <arm_group_label>L. Fermentum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females

          -  aged 18-60 yr

          -  plasma LDL-C 130-260 mg/dl

          -  TG levels below 400 mg/dl

          -  body mass index (BMI) rangewill be 22 to 32 kg/m2

          -  permitted to take stable doses of thyroid hormone and anti hypertensive agents, as
             long as these are continued equivalently throughout the duration of study

        Exclusion Criteria:

          -  history of recent (i.e. less than 3 mo) or chronic use of oral hypolipidemic therapy,
             including fish oils, or probucol within the last 6 mo, - history of chronic use of
             alcohol (&gt;2 drinks/d), systemic antibodies, corticosteroids, androgens, or phenytoin,

          -  myocardial infarction, coronary artery bypass, or other major surgical procedures
             within the last six months

          -  recent onset of angina, congestive heart failure, inflammatory bowel disease,
             pancreatitis, diabetes, lactose intolerance or significant current (ie. onset within
             past three months) gastrointestinal, renal, pulmonary, hepatic or biliary disease, or
             cancer (evidence of active lesions, chemotherapy or surgery in the past year

          -  chronic user of probiotics, fiber laxative (greater than 2 doses/wk), or stimulant
             laxatives or has a history of eating disorders, exercise greater than 15 miles/wk or
             4,000 kcal/wk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Peter Jones, Director of RCFFN</name_title>
    <organization>RCFFN, University of Manitoba</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

